ZA947444B - Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide - Google Patents
Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamideInfo
- Publication number
- ZA947444B ZA947444B ZA947444A ZA947444A ZA947444B ZA 947444 B ZA947444 B ZA 947444B ZA 947444 A ZA947444 A ZA 947444A ZA 947444 A ZA947444 A ZA 947444A ZA 947444 B ZA947444 B ZA 947444B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrolidineacetamide
- anxiety
- oxo
- alpha
- ethyl
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939319732A GB9319732D0 (en) | 1993-09-24 | 1993-09-24 | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA947444B true ZA947444B (en) | 1995-05-11 |
Family
ID=10742476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA947444A ZA947444B (en) | 1993-09-24 | 1994-09-23 | Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5447952A (no) |
| EP (1) | EP0645139B1 (no) |
| JP (1) | JP3688735B2 (no) |
| KR (1) | KR950007848A (no) |
| AT (1) | ATE191849T1 (no) |
| AU (1) | AU672334B2 (no) |
| CA (1) | CA2132509A1 (no) |
| DE (1) | DE69424009T2 (no) |
| ES (1) | ES2145818T3 (no) |
| GB (1) | GB9319732D0 (no) |
| HU (1) | HU217124B (no) |
| NO (1) | NO943521L (no) |
| NZ (1) | NZ264506A (no) |
| RU (1) | RU2142274C1 (no) |
| SG (1) | SG86284A1 (no) |
| TW (1) | TW283642B (no) |
| ZA (1) | ZA947444B (no) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525347A (en) * | 1995-01-31 | 1996-06-11 | Medical University Of South Carolina | Composition and methods for treating performance anxiety |
| EP1600167A3 (en) | 1999-12-01 | 2009-09-30 | Ucb, S.A. | A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| DE602006003617D1 (de) * | 2006-01-24 | 2008-12-24 | Teva Pharma | Zusammensetzungen enthaltend Levetiracetam und Verfahren zu deren Herstellung. |
| UA93903C2 (ru) * | 2006-03-15 | 2011-03-25 | Актелион Фармасьютикалз Лтд | Производные тетрагидроизохинолина для повышения функции памяти |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| JP2010531871A (ja) * | 2007-07-03 | 2010-09-30 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．３．０］オクタン化合物 |
| AU2008281399A1 (en) * | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
| WO2010044878A1 (en) * | 2008-10-16 | 2010-04-22 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US8191547B2 (en) * | 2008-10-23 | 2012-06-05 | S-2Tech Llc | Portable solar-heating system having an inflatable solar collector |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| US20100159009A1 (en) * | 2008-12-24 | 2010-06-24 | Zhongshui Yu | Controlled-release formulations |
| US20110212928A1 (en) * | 2010-02-09 | 2011-09-01 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| RU2665021C2 (ru) * | 2011-02-09 | 2018-08-24 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивных функций |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
| EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
| KR20210099567A (ko) * | 2018-12-04 | 2021-08-12 | 메티스 파마슈티칼스 아게 | (r)-2-(2-옥소피롤리딘-1-일)부탄아미드 및 (s)-2-(2-옥소피롤리딘-1-일)부탄아미드를 비-라세미 비로 포함하는 상승작용적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB8827389D0 (en) | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
-
1993
- 1993-09-24 GB GB939319732A patent/GB9319732D0/en active Pending
-
1994
- 1994-09-20 HU HU9402704A patent/HU217124B/hu not_active IP Right Cessation
- 1994-09-20 CA CA002132509A patent/CA2132509A1/en not_active Abandoned
- 1994-09-20 US US08/309,186 patent/US5447952A/en not_active Expired - Lifetime
- 1994-09-21 TW TW083108691A patent/TW283642B/zh active
- 1994-09-21 DE DE69424009T patent/DE69424009T2/de not_active Expired - Lifetime
- 1994-09-21 ES ES94870152T patent/ES2145818T3/es not_active Expired - Lifetime
- 1994-09-21 EP EP94870152A patent/EP0645139B1/fr not_active Expired - Lifetime
- 1994-09-21 AT AT94870152T patent/ATE191849T1/de not_active IP Right Cessation
- 1994-09-21 SG SG9502212A patent/SG86284A1/en unknown
- 1994-09-21 NZ NZ264506A patent/NZ264506A/en unknown
- 1994-09-22 AU AU74169/94A patent/AU672334B2/en not_active Ceased
- 1994-09-22 NO NO943521A patent/NO943521L/no unknown
- 1994-09-22 JP JP22833194A patent/JP3688735B2/ja not_active Expired - Fee Related
- 1994-09-23 RU RU94034109A patent/RU2142274C1/ru active
- 1994-09-23 KR KR1019940024170A patent/KR950007848A/ko active IP Right Grant
- 1994-09-23 ZA ZA947444A patent/ZA947444B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW283642B (no) | 1996-08-21 |
| EP0645139A1 (fr) | 1995-03-29 |
| DE69424009T2 (de) | 2000-09-14 |
| AU672334B2 (en) | 1996-09-26 |
| NO943521D0 (no) | 1994-09-22 |
| AU7416994A (en) | 1995-04-06 |
| JP3688735B2 (ja) | 2005-08-31 |
| KR950007848A (ko) | 1995-04-15 |
| HUT68299A (en) | 1995-06-28 |
| NZ264506A (en) | 1997-09-22 |
| NO943521L (no) | 1995-03-27 |
| RU2142274C1 (ru) | 1999-12-10 |
| HU217124B (hu) | 1999-11-29 |
| CA2132509A1 (en) | 1995-03-25 |
| ES2145818T3 (es) | 2000-07-16 |
| SG86284A1 (en) | 2002-02-19 |
| ATE191849T1 (de) | 2000-05-15 |
| EP0645139B1 (fr) | 2000-04-19 |
| GB9319732D0 (en) | 1993-11-10 |
| JPH07149639A (ja) | 1995-06-13 |
| DE69424009D1 (de) | 2000-05-25 |
| US5447952A (en) | 1995-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW283642B (no) | ||
| TW224942B (no) | ||
| EP0562049A4 (en) | Novel 4-arylpiperazines and 4-arylpiperidines | |
| ZA925128B (en) | Pyrrolidine derivatives,their preparation and medicaments containing them | |
| GR3022072T3 (en) | Treatment of neurodegenerative diseases | |
| GB9514473D0 (en) | Chemical compounds | |
| AU3354895A (en) | Novel medicinal use of 5ht3 antagonist | |
| GR3005470T3 (no) | ||
| EP0455448A3 (en) | Treatment of pancreatic disease with 15-keto-prostaglandin compounds | |
| GR3019760T3 (en) | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | |
| JPS6468368A (en) | Use of 2-pyrimidinyl-1-piperazine derivative | |
| GR3018674T3 (en) | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds | |
| GR3022217T3 (en) | Treatment of cataract with prostacyclin compounds | |
| NO920984D0 (no) | Fremgangsmaate for diastereoselektiv reduktiv pinakol-kobling av homokirale alfa-aminoaldehyder | |
| EP0377127A3 (de) | Verwendung von Myricetin-3-0-beta-D-glucuronid als Arzneimittel | |
| ZA88639B (en) | Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned | |
| IN172911B (no) | ||
| CY2065B1 (en) | Use of naphthoxazines | |
| GR3003065T3 (en) | Use of n-((1-ethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoyl benzamide in the treatment of sterility | |
| ZA917001B (en) | Medicaments containing substituted 2-cyclohexene derivates and their use for the control of diseases | |
| FI882388A0 (fi) | 4-substituerad 10-cyanmetylenpyrrolo /4,3-e/benzoazepin. | |
| TW234715B (no) | ||
| ZA937179B (en) | Tetrahydorindazolone pharmaceutical compositions | |
| ES2103166A1 (es) | Procedimiento para la obtencion de amidinohidrazonas biciclicas. | |
| ZA839573B (en) | Novel 6alpha-methylprednisolone derivatives and their manufacture and use |